Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. - Archive ouverte HAL Access content directly
Journal Articles Journal of Clinical Oncology Year : 2007

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

, , (1) , , , , , , , ,
1
Edith A. Perez
  • Function : Author
Guillermo L. Lerzo
  • Function : Author
Eva S. Thomas
  • Function : Author
Linda T. Vahdat
  • Function : Author
Linda Bosserman
  • Function : Author
Patrice Viens
  • Function : Author
Can Cai
  • Function : Author
Brian Mullaney
  • Function : Author
Ronald A. Peck
  • Function : Author
Gabriel N. Hortobagyi
  • Function : Author

Abstract

PURPOSE: To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study. PATIENTS AND METHODS: Patients with measurable disease who had tumor progression while receiving prior anthracycline, taxane, and capecitabine were enrolled. Ixabepilone 40 mg/m(2) monotherapy was administered as a 3-hour intravenous infusion on day 1 of a 21-day cycle. The primary end point was objective response rate (ORR), assessed by an independent radiology facility (IRF). RESULTS: A total of 126 patients were treated and 113 were assessable for response. Patients were heavily pretreated: 88% had received at least two lines of prior chemotherapy in the metastatic setting. IRF-assessed ORR was 11.5% (95% CI, 6.3% to 18.9%) for response-assessable patients. Investigator-assessed ORR for all treated patients was 18.3% (95% CI, 11.9% to 26.1%). Fifty percent of patients achieved stable disease (SD); 14.3% achieved SD >or= 6 months. Median duration of response and progression-free survival were 5.7 and 3.1 months, respectively. Median overall survival was 8.6 months. Patients received a median of 4.0 treatment cycles (range, one to 16 cycles), and 25% of patients received >or= eight cycles. Grade 3/4 treatment-related events included peripheral sensory neuropathy (14%), fatigue/asthenia (13%), myalgia (8%), and stomatitis/mucositis (6%). Resolution of grade 3/4 peripheral sensory neuropathy occurred after a median period of 5.4 weeks. CONCLUSION: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine. Responses were durable and notable in patients who had not previously responded to multiple prior therapies.
Not file

Dates and versions

inserm-00479743 , version 1 (23-05-2010)

Identifiers

Cite

Edith A. Perez, Guillermo L. Lerzo, Xavier B. Pivot, Eva S. Thomas, Linda T. Vahdat, et al.. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.. Journal of Clinical Oncology, 2007, 25 (23), pp.3407-14. ⟨10.1200/JCO.2006.09.3849⟩. ⟨inserm-00479743⟩

Collections

INSERM UNIV-FCOMTE
70 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More